Synlogic Obtains $40,000,000 Series B Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    130 Brookline St. Cambridge, MA 02139 USA
  • Company Description
    Synlogic leverages the most advanced technology platform available for the creation of synthetically engineered, therapeutic microbes with the potential to make significant advancements in the treatment of disease.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The additional funds will support the development efforts of our two lead inborn errors of metabolism programs, UCD and PKU, which we plan to advance to the clinic in early 2017, as well as expand our pipeline of Synthetic Biotics across multiple therapeutic areas. This financing together with our recently announced partnership with AbbVie for the treatment of inflammatory bowel diseases, positions Synlogic well to realize the transformative potential of this new class of medicines.
  • M&A Terms
  • Venture Investor
  • Venture Investor
    Deerfield Capital
  • Venture Investor
  • Venture Investor
    New Enterprise Associates

Trending on Xconomy